SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability.- SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments
- The two sides aim to submit an Investigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business
- SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical therapy pipeline and capability, via strengthened internal resources and partnerships
- 韩国生物医药公司Sk Biopharmaceuticals和韩国放射医学科学研究所合作，利用发射阿尔法粒子的放射性同位素镥-225，共同发现和开发放射性药物候选化合物，用于潜在的癌症治疗。
- 双方旨在根据Sk Biopharmaceuticals加强放射性药物治疗业务的路线图，于2027年前提交新药探索申请。
- Sk Biopharmaceuticals通过加强内部资源和合作伙伴关系，进一步加快了其放射性药物治疗管线和能力的扩展。
SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates.
2024年11月18日，韩国首尔／PRNewswire／—生物科技公司Sk Biopharmaceuticals宣布，已与韩国放射医学科学研究所（KIRAMS）达成协议，韩国放射医学科学研究所是韩国主要研究机构，致力于放射医学科学的研究与推动，双方合作共同发现和开发临床前放射性药物候选化合物。
This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac), an alpha-particle emitting radioisotope that selectively kills cancer cells. The research for radiopharmaceutical therapy (RPT) focuses on this application that has been gaining attention for its high potential in nuclear medicine.
这标志着双方的首个合作研究协议，双方将致力于发现放射性药物化合物，并探索新型肿瘤治疗方法，使用能选择性杀灭癌细胞的发射阿尔法粒子的放射性同位素镥-225（225Ac）。放射性药物治疗（RPT）的研究专注于核医学领域备受关注的这一应用。
SK Biopharmaceuticals has already initiated its 225Ac-based research as it secured a supply of the radioisotope from TerraPower Isotopes, a subsidiary of TerraPower, a nuclear innovation company whose investors include SK Biopharmaceuticals' parent SK Inc. and Bill Gates.
Sk Biopharmaceuticals已开始其基于225Ac的研究，因其从TerraPower Isotopes获得了这种放射性同位素供应，TerraPower Isotopes是TerraPower的子公司，TerraPower是一家核创新公司，其投资者包括Sk Biopharmaceuticals的母公司Sk Inc.和比尔·盖茨。
SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability.
Sk Biopharmaceuticals和KIRAMS将利用彼此的资源，优化他们的药物发现工作，力求在2027年前提交新药探索申请。Sk Biopharmaceuticals表示，借助KIRAMS的研究人员、设施和设备，使用该放射性同位素，可以显著减少新药研发的时间和成本，使公司进一步加速获得和扩展其RPT管线和能力。
The agreement is in line with SK Biopharmaceuticals' so-called "RPT Roadmap" recently introduced to become a global leading RPT player by 2027, as the company will fortify its RPT business by discovering new drug compounds, extending supply and production capacities, and developing a tech platform, via strengthened internal assets and strategic partnerships.
该协议符合Sk生物制药最近推出的“RPt路线图”，目标是到2027年成为全球领先的RPt参与者，该公司将通过发现新药物化合物、扩展供应和生产能力以及开发技术平台来加强其RPt业务，通过加强内部资产和战略合作伙伴关系。
In addition to the 225Ac supply agreement aligned with its roadmap, the company has in-licensed SKL35501 (FL-091) radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) solid tumors.
除了与其路线图一致的225Ac供应协议外，公司还已批准了瞄准神经犬饮水系统素受体1(NTSR1)实体瘤的SKL35501(FL-091)放射药物化合物。
Jinkyung Lee, President of KIRAMS, stated, "Through this joint research agreement, we aim to take a leading role in developing innovative radiopharmaceutical therapeutics, in alignment with the Ministry of Science and ICT's strategic initiative to drive advancements in Radiation Biology. We look forward to contributing to the growth of the domestic radiopharmaceutical industry in close collaboration with SK Biopharmaceuticals."
KIRAMS总裁李真京表示：“通过这项联合研究协议，我们旨在在开展创新性放射药物治疗方面发挥主导作用，配合科技部科技与信息通信部的战略倡议推动放射生物学进展。我们期待与Sk生物制药密切合作，为国内放射药物行业的增长做出贡献。”
Donghoon Lee, CEO and President of SK Biopharmaceuticals, said "This agreement is one of key steps in enhancing SK Biopharmaceuticals' research capabilities. We will seek to spur SK Biopharmaceuticals to become a leading global RPT player through strengthened ties."
Sk生物制药的首席执行官兼总裁李东勋表示：“该协议是增强Sk生物制药研究能力的关键步骤之一。我们将致力于通过加强联系推动Sk生物制药成为全球领先的RPt参与者。”
About SK Biopharmaceuticals
关于Sk生物制药
SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts.
Sk生物制药专注于中枢神经系统(CNS)和肿瘤治疗的研究、开发和商业化。2017年，Sk生物制药成立了一个研究中心，通过研究和开发努力进军肿瘤领域。
SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa.
Sk生物制药是首家也是唯一一家独立在美国研发和商业化抗癫痫药物的韩国公司，其品牌为XCOPRI的瑟诺巴酮。自2020年在美国推出以来，全球已有超过10万患者接受了由Sk生物制药及其美国子公司Sk Life Science, Inc.开发的瑟诺巴酮治疗。瑟诺巴酮已成功进入北美、欧洲、亚洲、中南美洲以及中东北非五个主要地区。
The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at , and SK Life Science's website at .
该公司还开发了八种化合物，用于中枢神经系统疾病和肿瘤的治疗。此外，爱文思控股致力于在肿瘤领域发现新疗法。欲了解更多信息，请访问爱文思控股的网站，以及Sk Life Science的网站。
About Korea Institute of Radiological and Medical Sciences
关于韩国放射医学科学研究所
As a premier institution dedicated to the intersection of science, technology, and healthcare, the Korea Institute of Radiological and Medical Sciences (KIRAMS) is at the forefront of radiation medicine innovation.
作为致力于科学、科技和医疗交叉领域的顶尖机构，韩国放射医学科学研究所（KIRAMS）位于放射医学创新的前沿。
Ever since KIRAMS opened its doors as a radiation medicine research center in 1963, we have been contributing to the national development of science and technology, and to the promotion of the health of the people, based on our research in medical uses of radiation.
自1963年韩国放射医学科学研究所作为放射医学研究中心开放以来，我们一直在基于放射医学研究为国家科技发展和人民健康促进做出贡献。
By bringing the very first Cobalt-60 radiotherapy machine for cancer treatment to Korea in 1963, we were able to greatly increase the number of completely cured cancer patients. Following the restructuring of a cancer hospital in 1973, KIRAMS was leading domestic cancer treatment until the 1990s, by introducing diagnostic and treatment technologies that incorporated advanced science. In 2007, we became an independent institution, directly under the Ministry of Science and ICT, and since then we have established "Radiation Medicine" as a separate field of research and distinguished ourselves from other medical institutes by expanding the National Radiation Emergency Medical Center.
1963年，我们将第一台钴60放射治疗机引入韩国，极大地增加了癌症完全治愈患者的数量。随着1973年癌症医院的重组，KIRAMS在1990年代之前一直领先于国内癌症治疗，引入了融合先进科学的诊断和治疗技术。2007年，我们成为直属于科技部的独立机构，从那时起，我们将“放射医学”确立为一个独立的研究领域，并通过扩建国家放射应急医疗中心，使自己与其他医学研究机构区分开来。
And now, going beyond our original mission of defeating cancer, KIRAMS is evolving into a public institution committed to solving new problems for the country and for society, as well as for the benefit of the people. In other words, we are opening new horizons in radiation medicine by supporting specialized, research-centric hospitals engaged in advanced biomedical R&D, by consolidating research and detection of radiation in everyday life, which has recently become a social issue, and by establishing and operating the new Radioisotope Center for Pharmaceuticals to promote the research and use of radioisotopes for medical purposes.
如今，韩国放射医学科学研究所已超越战胜癌症的最初使命，发展为致力于为国家和社会解决新问题，造福于人民的公共机构。换句话说，我们通过支持从事先进生物医药研发的专业研究型医院，整合放射检测研究，将射线科技在日常生活中的应用也成为社会问题，并设立并运营新的药物放射同位素中心，促进射线同位素在医学领域的研究和应用，开创了放射医学的新局面。
Leveraging our extensive experience and our accomplishments, we here at the Korea Institute of Radiological and Medical Sciences will not rest but continually develop into the number one specialist institute for radiotherapy trusted by the people.
凭借我们丰富的经验和成就，在韩国放射医学科学研究院，我们不会停止，将不断发展成为备受人们信赖的放射治疗专业机构。
For more information, visit .
欲了解更多信息，请访问 。
SOURCE SK Biopharmaceuticals Co., Ltd
资讯 SK生物制药有限公司
